Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | EIF4E | P06730 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TOP1 | P11387 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ATG7 | O95352 | 6/20 | 0.38 |
| ▸ | ADK | P55263 | 3/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232095 | 0.90 | PNP (0.46) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL15788463 | 0.90 | PNP (0.73) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL15788414 | 0.89 | LMNA (0.59) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL18744112 | 0.86 | PNP (0.79) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL17232092 | 0.85 | LMNA (0.46) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL13614236 | 0.81 | PNP (0.55) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL17232105 | 0.79 | PNP (0.57) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL18744101 | 0.78 | PNP (0.70) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL18744095 | 0.78 | LMNA (0.57) | PNPLMNASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL12151510 | 0.78 | LMNA (0.73) | PNPLMNASMN1; SMN2ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624249-B2 | Nucleoside kinase bypass compositions and methods | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2014088923-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | DCK, DTYMK, TK1 | PNP 30/4885LMNA 4073/4885SMN1; SMN2 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.